Latest News and Press Releases
Want to stay updated on the latest news?
-
Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044Sol-Gel completed an oversubscribed underwritten...
-
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
-
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
-
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
-
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
-
Sol-Gel Announces Health Canada Approval of EPSOLAY®
-
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
-
Sol-Gel Reports First Quarter 2025 Results
-
Sol-Gel Announces Reverse Share Split
-
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.